skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels

Journal Article · · Journal of Cardiovascular Pharmacology; (USA)

In vivo and in vitro methods were used to characterize AHR-16303B, a novel compound with antagonistic action at 5-HT2 receptors and voltage-sensitive calcium channels. The 5-HT2 receptor-antagonistic properties of AHR-16303B were demonstrated by inhibition of (a) (3H)ketanserin binding to rat cerebral cortical membranes (IC50 = 165 nM); (b) 5-hydroxytryptamine (5-HT)-induced foot edema in rats (minimum effective dose, (MED) = 0.32 mg/kg orally, p.o.); (c) 5-HT-induced vasopressor responses in spontaneously hypertensive rats (SHR) (ID50 = 0.18 mg/kg intravenously (i.v.), 1.8 mg/kg p.o.), (d) 5-HT-induced antidiuresis in rats (MED = 1 mg/kg p.o.), and (e) platelet aggregation induced by 5-HT + ADP (IC50 = 1.5 mM). The calcium antagonist properties of AHR-16303B were demonstrated by inhibition of (a) (3H)nimodipine binding to voltage-sensitive calcium channels on rabbit skeletal muscle membranes (IC50 = 15 nM), (b) KCl-stimulated calcium flux into cultured PC12 cells (IC50 = 81 nM), and (c) CaCl2-induced contractions of rabbit thoracic aortic strips (pA2 = 8.84). AHR-16303B had little or no effect on binding of radioligands to dopamine2 (DA2) alpha 1, alpha 2, H1, 5-HT1 alpha, beta 2, muscarinic M1, or sigma opioid receptors; had no effect on 5-HT3 receptor-mediated vagal bradycardia; and had only minor negative inotropic, chronotropic, and dromotropic effects on isolated guinea pig atria. In conscious SHR, 30 mg/kg p.o. AHR-16303B completely prevented the vasopressor responses to i.v. 5-HT, and decreased blood pressure (BP) by 24% 3 h after dosing.

OSTI ID:
5644005
Journal Information:
Journal of Cardiovascular Pharmacology; (USA), Vol. 17:1; ISSN 0160-2246
Country of Publication:
United States
Language:
English

Similar Records

Pharmacological characterization of LY233053: A structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action
Journal Article · Sat Dec 01 00:00:00 EST 1990 · Journal of Pharmacology and Experimental Therapeutics; (USA) · OSTI ID:5644005

BMY 20064, a potent calcium channel blocker with. cap alpha. /sub 1/-adrenoceptor antagonist properties
Journal Article · Wed Mar 05 00:00:00 EST 1986 · Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) · OSTI ID:5644005

Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-( sup 125 I) iodophenyl)-2-aminopropane (( sup 125 I)DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain
Journal Article · Thu Nov 01 00:00:00 EST 1990 · Journal of Pharmacology and Experimental Therapeutics; (USA) · OSTI ID:5644005